CaroSpir is an oral liquid suspension dosage form of the potassium-sparing diuretic spironolactone and comes in the strength of 25 milligrams (mg) per 5 milliliters (mL).

Spironolactone was first approved in tablet form under the brand name Aldactone in 1960. It is widely available as a generic.

CaroSpir was approved in 2017 as the first and only FDA-approved oral liquid dosage form of spironolactone. It provides a liquid treatment option for adult patients including those who have difficulty swallowing, or who cannot swallow tablets.

CaroSpir is indicated for:

• the treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure.
• use as an add-on therapy for the treatment of hypertension, to lower blood pressure.
• myocardial infarctions
• the management of edema in adult cirrhotic patients when edema is not responsive to fluid and sodium restrictions.

CaroSpir is not therapeutically equivalent to Aldactone or tablet forms of spironolactone. CaroSpir can produce 15 to 37% higher serum concentrations of spironolactone when compared to tablets.